GSK Agrees to $357 Million Exclusive License Agreement
GSK has secured exclusive rights to Syndivia's promising ADC for metastatic castration-resistant prostate cancer, enhancing treatment options for patients.
GSK is set to acquire the exclusive rights for Syndivia’s preclinical antibody-drug conjugate (ADC), which is currently in development for the treatment of Metastatic castration-resistant prostate cancer (mCRPC).
The agreement grants GSK the exclusive rights to the development and commercialization of the ADC worldwide.
Sasha Koniev, chief executive officer at Syndivia, said, “We are proud that GSK will advance this program on a global scale. This agreement underscores the value of our GeminiMab ADC platform and the opportunity to bring a promising new therapy to patients with pressing unmet medical needs.
Author's summary: GSK secures exclusive rights to Syndivia's ADC.
More News
- Selling Sunset's Mary Bonnet Thinks Producers Set Up Chelsea Conflict
- Stevie Nicks and Lindsey Buckingham Call Truce, Appear Together on Song Exploder Podcast
- Xbox Network and Minecraft Go Down After Major Microsoft Azure Outage | iPhone in Canada
- US Determined to Prevent the Collapse of the Gaza Ceasefire After Overnight Airstrikes
- 'Selling Sunset' Star Chrishell Stause Calls Her Parents 'Bad *sses' After Fiery Confrontation With Nicole Young
- American Red Cross Steps Up As Government Shutdown Impacts Military Pay, SNAP
- Apple stock gets $320 target from BofA ahead of Q4 earnings - 9to5Mac
- Hansa hosts call with distinguished transplant surgeons: Insights on clinical practice and imlifidase Phase 3 Results
- Regeneron receives another CRL for its Eyelea 8 mg | Ophthalmology Times - Clinical Insights for Eye Specialists
- 'Down Cemetery Road' Release Schedule: When Are New Episodes Out?